145 related articles for article (PubMed ID: 25710919)
1. Next steps for cancer immune therapy.
Cancer Discov; 2015 Mar; 5(3):221-2. PubMed ID: 25710919
[No Abstract] [Full Text] [Related]
2. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
Afreen S; Dermime S
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):1-17. PubMed ID: 24398144
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
4. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
5. MICROBIOME. Microbes aid cancer drugs.
Leslie M
Science; 2015 Nov; 350(6261):614-5. PubMed ID: 26542545
[No Abstract] [Full Text] [Related]
6. The science of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
[No Abstract] [Full Text] [Related]
7. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS; Irving BA; Hodi FS
Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 antibody active in metastatic bladder cancer.
Brower V
Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
[No Abstract] [Full Text] [Related]
10. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
11. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
13. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
14. [Immunology: new approaches to immuno-modulation and immunotherapy].
Kabelitz D
Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1471-3. PubMed ID: 16794979
[No Abstract] [Full Text] [Related]
15. A Potential Immune Therapy for Mesothelioma.
Cancer Discov; 2015 Jul; 5(7):OF14. PubMed ID: 25956959
[No Abstract] [Full Text] [Related]
16. PD-L1 blockade for cancer treatment: MEDI4736.
Ibrahim R; Stewart R; Shalabi A
Semin Oncol; 2015 Jun; 42(3):474-83. PubMed ID: 25965366
[TBL] [Abstract][Full Text] [Related]
17. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
[No Abstract] [Full Text] [Related]
18. Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy.
Reisfeld RA; Cheresh DA
Cancer Surv; 1985; 4(1):271-90. PubMed ID: 3916082
[No Abstract] [Full Text] [Related]
19. [Cancer immunotherapy].
Vakkila J; Pihkala U
Duodecim; 1999; 115(7):785-94. PubMed ID: 11859512
[No Abstract] [Full Text] [Related]
20. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
